Tritonpoint Wealth LLC Trims Position in Zoetis Inc. $ZTS

Tritonpoint Wealth LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 25.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 22,171 shares of the company’s stock after selling 7,765 shares during the period. Tritonpoint Wealth LLC’s holdings in Zoetis were worth $3,457,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZTS. Nova Wealth Management Inc. purchased a new position in Zoetis during the 1st quarter valued at about $25,000. 1248 Management LLC purchased a new position in Zoetis during the 1st quarter valued at about $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC increased its holdings in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares during the period. Finally, ORG Partners LLC increased its holdings in Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after buying an additional 84 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.7%

NYSE:ZTS opened at $143.52 on Friday. The company has a market cap of $63.61 billion, a PE ratio of 24.70, a P/E/G ratio of 2.30 and a beta of 0.89. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $197.51. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company’s 50 day moving average is $150.35 and its two-hundred day moving average is $155.67.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Zoetis presently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.